Ifteni Petru, Teodorescu Andreea, Moga Marius Alexandru, Pascu Alina Mihaela, Miclaus Roxana Steliana
Faculty of Medicine, Transilvania University of Brasov, Brasov, Romania; Clinical Hospital of Psychiatry and Neurology Brasov, Brasov, Romania.
Faculty of Medicine, Transilvania University of Brasov, Brasov, Romania.
Neuropsychiatr Dis Treat. 2017 Jan 23;13:201-204. doi: 10.2147/NDT.S122367. eCollection 2017.
Bipolar disorder (BD) is associated with periodic symptom exacerbations, leading to functional impairment, and increased risk of suicide. Although clozapine has never been approved for the treatment of BD, it is occasionally used in severe mania. The aim of the study is to evaluate the risks and benefits of switching clozapine in remitted BD patients. This is an observational, mirror image study of 62 consecutive remitted BD outpatients treated with clozapine. Twenty-five patients were switched to another antipsychotic following a change in a drug reimbursement rule, while 37 continued on clozapine. The mean time in remission was shorter for the switched group (9.2±4 months vs 13±6 months, =0.018), and the number of patients who relapsed was larger (n=21 vs n=8, <0.0001). The results suggest that switching from clozapine to another antipsychotic may increase the risk of relapses in remitted patients with BD.
双相情感障碍（BD）与周期性症状加重有关，会导致功能障碍，并增加自杀风险。尽管氯氮平从未被批准用于治疗BD，但偶尔会用于严重躁狂发作。本研究的目的是评估在BD缓解期患者中换用氯氮平的风险和益处。这是一项对62例连续接受氯氮平治疗的BD缓解期门诊患者进行的观察性镜像研究。25例患者因药物报销规定的变化而换用另一种抗精神病药物，而37例患者继续使用氯氮平。换药组的平均缓解时间较短（9.2±4个月对13±6个月，P = 0.018），复发患者数量较多（n = 21对n = 8，P<0.0001）。结果表明，从氯氮平换用另一种抗精神病药物可能会增加BD缓解期患者复发的风险。
